Clinical trial results:
A Biomarker-Directed Phase 2 Trial of SY-1425, a Selective Retinoic Acid Receptor Alpha Agonist, in Adult Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Summary

EudraCT number	2017-000783-14
Trial protocol	FR
Global end of trial date	25 January 2023

Results information

Result version number	v1 (current)
This version publication date	11 February 2024
First version publication date	11 February 2024

Trial information

Trial identification

Sponsor protocol code	SY-1425-201

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02807558
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Syros Pharmaceuticals, Inc.
Sponsor organisation address	35 CambridgePark Drive, 4th Floor, Cambridge, United States, 02140
Public contact	Jason Haas, Syros Pharmaceuticals Inc., jhaas@syros.com
Scientific contact	Emily Fearnow, Syros Pharmaceuticals Inc., efearno@syros.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	25 January 2023
Is this the analysis of the primary completion data?	Yes
Primary completion date	25 January 2023
Global end of trial reached?	Yes
Global end of trial date	25 January 2023
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The purpose of this study is to determine the activity of tamibarotene in participants with relapsed/refractory (R/R) AML (administered as a monotherapy or in combination with azacitidine), R/R higher-risk MDS (HR-MDS)(administered as a monotherapy or in combination with daratumumab), newly diagnosed (ND) treatment naïve AML participants who are unlikely to tolerate standard intensive chemotherapy (administered as a monotherapy or in combination with azacitidine), or lower-risk MDS (LR-MDS) (administered as a monotherapy).

Protection of trial subjects:

This study was conducted according to the protocol, the ethical principles that have their origins in the Declaration of Helsinki, including the current International Council for Harmonisation (ICH) Good Clinical Practice (GCP) Consolidated Guideline E6 (R2), and all applicable national and local laws and regulations.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	20 September 2016
Long term follow-up planned	Yes
Long term follow-up rationale	Safety, Efficacy
Long term follow-up duration	2 Years
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	France: 47
Country: Number of subjects enrolled	United States: 108
Worldwide total number of subjects	155
EEA total number of subjects	47

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0

Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	20
From 65 to 84 years	122
85 years and over	13

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

Screening assessments were conducted within 30 days of dosing.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	R/R Non-APL AML or R/R HR-MDS: Tamibarotene Monotherapy

Arm description:

Participants with R/R non-APL AML or R/R HR-MDS received tamibarotene at 6 mg/m^2/day in 2 divided doses on Days 1-28 of a 28-day cycle

Arm type	Experimental
Investigational medicinal product name	Tamibarotene
Investigational medicinal product code	
Other name	SY-1425
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Administered as specified in the treatment arm.

Arm title	Newly Diagnosed Non-APL AML: Tamibarotene Monotherapy

Arm description:

Newly diagnosed, treatment-naive participants with non-APL AML who were unlikely to tolerate standard intensive chemotherapy received tamibarotene at 6 mg/m^2/day in 2 divided doses on Days 1-28 of a 28- day cycle

Arm type	Experimental
Investigational medicinal product name	Tamibarotene
Investigational medicinal product code	
Other name	SY-1425
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Administered as specified in the treatment arm.

Arm title	LR-MDS: Tamibarotene Monotherapy

Arm description:

Participants with transfusion-dependent lower-risk myelodysplastic syndrome (LR-MDS) without the del-5q abnormality who were refractory to erythropoietin (EPO) treatment or unlikely to respond to EPO treatment received tamibarotene at 6 mg/m^2/day in 2 divided doses from Days 1-28 of a 28-day cycle

Arm type	Experimental

Investigational medicinal product name	Tamibarotene
Investigational medicinal product code	
Other name	SY-1425
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Administered as specified in the treatment arm.

Arm title	Newly Diagnosed Non-APL AML: Tamibarotene and Azacitidine

Arm description:

Newly diagnosed, treatment-naive participants with non-APL AML who were unlikely to tolerate standard intensive chemotherapy received tamibarotene at 6 mg/m^2/day in 2 divided doses on Days 8-28 of a 28-day cycle, and azacitidine at 75 mg/m^2 once daily on Days 1-7 of a 28-day cycle

Arm type	Experimental
Investigational medicinal product name	Azacitidine
Investigational medicinal product code	
Other name	Vidaza
Pharmaceutical forms	Injection/infusion
Routes of administration	Solution for infusion

Dosage and administration details:

Administered as specified in the treatment arm.

Investigational medicinal product name	Tamibarotene
Investigational medicinal product code	
Other name	SY-1425
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Administered as specified in the treatment arm.

Arm title	R/R non-APL AML: Tamibarotene and Azacitidine

Arm description:

Participants with R/R non-APL AML received tamibarotene at 6 mg/m^2/day in 2 divided doses on Days 8-28 of a 28-day cycle, and azacitidine at 75 mg/m^2 once daily on Days 1-7 of a 28-day cycle

Arm type	Experimental
Investigational medicinal product name	Azacitidine
Investigational medicinal product code	
Other name	Vidaza
Pharmaceutical forms	Injection/infusion
Routes of administration	Solution for infusion

Dosage and administration details:

Administered as specified in the treatment arm.

Investigational medicinal product name	Tamibarotene
Investigational medicinal product code	
Other name	SY-1425
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Administered as specified in the treatment arm.

Arm title	R/R non-APL AML or R/R HR-MDS: Tamibarotene and Daratumumab

Arm description:

Participants with R/R non-APL AML or R/R HR-MDS received tamibarotene at 6 mg/m^2/day in 2 divided doses during a 7-day lead-in and on Days 1-28 of a 28-day cycle. Participants also received daratumumab at 16 mg/kg starting on Cycle 1 Day 1 once weekly for 8 weeks, followed by dosing every 2 weeks for 16 weeks, followed by dosing every 4 weeks

Arm type	Experimental
Investigational medicinal product name	Daratumumab
Investigational medicinal product code	
Other name	Darzalex
Pharmaceutical forms	Injection/infusion
Routes of administration	Solution for infusion

Dosage and administration details:

Administered as specified in the treatment arm.

Investigational medicinal product name	Tamibarotene
Investigational medicinal product code	
Other name	SY-1425
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Administered as specified in the treatment arm.

Number of subjects in period 1	R/R Non-APL AML or R/R HR-MDS: Tamibarotene Monotherapy	Newly Diagnosed Non-APL AML: Tamibarotene Monotherapy	LR-MDS: Tamibarotene Monotherapy
Started	29	2	29
Received at Least 1 Dose of Study Drug	29	2	29
Response Evaluable Population	22	2	27
Completed per Study Protocol	29	2	29
Completed Post-Treatment Follow-Up	1	0	0
Evaluable for HI	16	2	25
Completed	1	0	0
Not completed	28	2	29
Consent withdrawn by subject	4	-	4
Non-compliance with Study Drug	-	-	1
Adverse event, non-fatal	-	-	9
Death	23	2	3
Progressive Disease	-	-	1
Other than specified	1	-	2
Lack of efficacy	-	-	9

Number of subjects in period 1	Newly Diagnosed Non-APL AML: Tamibarotene and Azacitidine	R/R non-APL AML: Tamibarotene and Azacitidine	R/R non-APL AML or R/R HR-MDS: Tamibarotene and Daratumumab
Started	51	28	16
Received at Least 1 Dose of Study Drug	51	28	16
Response Evaluable Population	46	21	12
Completed per Study Protocol	51	27	16
Completed Post-Treatment Follow-Up	6	1 [1]	0

Evaluable for HI	16	17	9
Completed	6	2	0
Not completed	45	26	16
Consent withdrawn by subject	2	1	-
Non-compliance with Study Drug	-	-	-
Adverse event, non-fatal	-	-	-
Death	43	24	15
Progressive Disease	-	-	-
Other than specified	-	1	1
Lack of efficacy	-	-	-

Notes:

[1] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Milestones were added to support data presented.

Baseline characteristics

Reporting groups	
Reporting group title	R/R Non-APL AML or R/R HR-MDS: Tamibarotene Monotherapy
Reporting group description:	
Participants with R/R non-APL AML or R/R HR-MDS received tamibarotene at 6 mg/m^2/day in 2 divided doses on Days 1-28 of a 28-day cycle	
Reporting group title	Newly Diagnosed Non-APL AML: Tamibarotene Monotherapy
Reporting group description:	
Newly diagnosed, treatment-naive participants with non-APL AML who were unlikely to tolerate standard intensive chemotherapy received tamibarotene at 6 mg/m^2/day in 2 divided doses on Days 1-28 of a 28- day cycle	
Reporting group title	LR-MDS: Tamibarotene Monotherapy
Reporting group description:	
Participants with transfusion-dependent lower-risk myelodysplastic syndrome (LR-MDS) without the del-5q abnormality who were refractory to erythropoietin (EPO) treatment or unlikely to respond to EPO treatment received tamibarotene at 6 mg/m^2/day in 2 divided doses from Days 1-28 of a 28-day cycle	
Reporting group title	Newly Diagnosed Non-APL AML: Tamibarotene and Azacitidine
Reporting group description:	
Newly diagnosed, treatment-naive participants with non-APL AML who were unlikely to tolerate standard intensive chemotherapy received tamibarotene at 6 mg/m^2/day in 2 divided doses on Days 8-28 of a 28-day cycle, and azacitidine at 75 mg/m^2 once daily on Days 1-7 of a 28-day cycle	
Reporting group title	R/R non-APL AML: Tamibarotene and Azacitidine
Reporting group description:	
Participants with R/R non-APL AML received tamibarotene at 6 mg/m^2/day in 2 divided doses on Days 8-28 of a 28-day cycle, and azacitidine at 75 mg/m^2 once daily on Days 1-7 of a 28-day cycle	
Reporting group title	R/R non-APL AML or R/R HR-MDS: Tamibarotene and Daratumumab
Reporting group description:	
Participants with R/R non-APL AML or R/R HR-MDS received tamibarotene at 6 mg/m^2/day in 2 divided doses during a 7-day lead-in and on Days 1-28 of a 28-day cycle. Participants also received daratumumab at 16 mg/kg starting on Cycle 1 Day 1 once weekly for 8 weeks, followed by dosing every 2 weeks for 16 weeks, followed by dosing every 4 weeks	

Reporting group values	R/R Non-APL AML or R/R HR-MDS: Tamibarotene Monotherapy	Newly Diagnosed Non-APL AML: Tamibarotene Monotherapy	LR-MDS: Tamibarotene Monotherapy
Number of subjects	29	2	29
Age categorical Units: Subjects			
Adults (18-64 years)	5	0	2
From 65-84 years	21	2	24
85 years and over	3	0	3
Age continuous Units: years			
arithmetic mean	70.3	74.5	76.1
standard deviation	± 13.27	± 3.54	± 8.40
Gender categorical Units: Subjects			
Female	12	0	10
Male	17	2	19

Race Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	1	0	0
Black Or African American	3	0	3
Native Hawaiian or Other Pacific Islander	0	0	0
White	25	0	22
Other	0	1	1
Not Reported	0	1	3
Ethnicity Units: Subjects			
Hispanic Or Latino	3	2	2
Not Hispanic Or Latino	25	0	25
Not Reported	1	0	2

Reporting group values	Newly Diagnosed Non-APL AML: Tamibarotene and Azacitidine	R/R non-APL AML: Tamibarotene and Azacitidine	R/R non-APL AML or R/R HR-MDS: Tamibarotene and Daratumumab
Number of subjects	51	28	16
Age categorical Units: Subjects			
Adults (18-64 years)	3	5	5
From 65-84 years	43	21	11
85 years and over	5	2	0
Age continuous Units: years			
arithmetic mean	76.0	72.0	62.9
standard deviation	± 6.89	± 12.19	± 13.36
Gender categorical Units: Subjects			
Female	19	15	8
Male	32	13	8
Race Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	2	1	0
Black Or African American	2	0	0
Native Hawaiian or Other Pacific Islander	0	0	0
White	30	18	14
Other	2	0	0
Not Reported	15	9	2
Ethnicity Units: Subjects			
Hispanic Or Latino	6	3	2
Not Hispanic Or Latino	29	16	13
Not Reported	16	9	1

Reporting group values	Total		
Number of subjects	155		

Age categorical Units: Subjects			
Adults (18-64 years)	20		
From 65-84 years	122		
85 years and over	13		
Age continuous Units: years arithmetic mean standard deviation	 -		
Gender categorical Units: Subjects			
Female	64		
Male	91		
Race Units: Subjects			
American Indian or Alaska Native	0		
Asian	4		
Black Or African American	8		
Native Hawaiian or Other Pacific Islander	0		
White	109		
Other	4		
Not Reported	30		
Ethnicity Units: Subjects			
Hispanic Or Latino	18		
Not Hispanic Or Latino	108		
Not Reported	29		

End points

End points reporting groups

Reporting group title	R/R Non-APL AML or R/R HR-MDS: Tamibarotene Monotherapy
Reporting group description:	
Participants with R/R non-APL AML or R/R HR-MDS received tamibarotene at 6 mg/m^2/day in 2 divided doses on Days 1-28 of a 28-day cycle	
Reporting group title	Newly Diagnosed Non-APL AML: Tamibarotene Monotherapy
Reporting group description:	
Newly diagnosed, treatment-naive participants with non-APL AML who were unlikely to tolerate standard intensive chemotherapy received tamibarotene at 6 mg/m^2/day in 2 divided doses on Days 1-28 of a 28- day cycle	
Reporting group title	LR-MDS: Tamibarotene Monotherapy
Reporting group description:	
Participants with transfusion-dependent lower-risk myelodysplastic syndrome (LR-MDS) without the del-5q abnormality who were refractory to erythropoietin (EPO) treatment or unlikely to respond to EPO treatment received tamibarotene at 6 mg/m^2/day in 2 divided doses from Days 1-28 of a 28-day cycle	
Reporting group title	Newly Diagnosed Non-APL AML: Tamibarotene and Azacitidine
Reporting group description:	
Newly diagnosed, treatment-naive participants with non-APL AML who were unlikely to tolerate standard intensive chemotherapy received tamibarotene at 6 mg/m^2/day in 2 divided doses on Days 8-28 of a 28-day cycle, and azacitidine at 75 mg/m^2 once daily on Days 1-7 of a 28-day cycle	
Reporting group title	R/R non-APL AML: Tamibarotene and Azacitidine
Reporting group description:	
Participants with R/R non-APL AML received tamibarotene at 6 mg/m^2/day in 2 divided doses on Days 8-28 of a 28-day cycle, and azacitidine at 75 mg/m^2 once daily on Days 1-7 of a 28-day cycle	
Reporting group title	R/R non-APL AML or R/R HR-MDS: Tamibarotene and Daratumumab
Reporting group description:	
Participants with R/R non-APL AML or R/R HR-MDS received tamibarotene at 6 mg/m^2/day in 2 divided doses during a 7-day lead-in and on Days 1-28 of a 28-day cycle. Participants also received daratumumab at 16 mg/kg starting on Cycle 1 Day 1 once weekly for 8 weeks, followed by dosing every 2 weeks for 16 weeks, followed by dosing every 4 weeks	
Subject analysis set title	ND Non-APL AML: Tamibarotene and Azacitidine: RARA-Positive
Subject analysis set type	Sub-group analysis
Subject analysis set description:	
Participants from the "Newly Diagnosed Non-APL AML:Tamibarotene and Azacitidine" arm who were positive for the RARA super-enhancer associated biomarker (RARA-positive) were included in this sub-group analysis. Participants who were unlikely to tolerate standard intensive chemotherapy received tamibarotene at 6 mg/m^2/day in 2 divided doses on Days 8-28 of a 28-day cycle, and azacitidine at 75 mg/m^2 once daily on Days 1-7 of a 28-day cycle.	
Subject analysis set title	ND Non-APL AML: Tamibarotene and Azacitidine: RARA-Negative
Subject analysis set type	Sub-group analysis
Subject analysis set description:	
Participants from the "Newly Diagnosed Non-APL AML:Tamibarotene and Azacitidine" arm who were negative for the RARA super-enhancer associated biomarker (RARA-negative) were included in this sub-group analysis. Participants who were unlikely to tolerate standard intensive chemotherapy received tamibarotene at 6 mg/m^2/day in 2 divided doses on Days 8-28 of a 28-day cycle, and azacitidine at 75 mg/m^2 once daily on Days 1-7 of a 28-day cycle.	

Primary: Overall Response Rate (ORR) in Biomarker Positive AML or HR-MDS Participants Treated With Tamibarotene Monotherapy or in Combination With Azacitidine

End point title	Overall Response Rate (ORR) in Biomarker Positive AML or HR-MDS Participants Treated With Tamibarotene Monotherapy or in Combination With Azacitidine[1][2]

End point description:

ORR was defined as: AML: number of participants with complete remission (CR), CR with incomplete blood count recovery (CRi), CR with partial hematologic recovery (CRh), partial remission(PR), or morphologic leukemia-free state (MLFS) determined by the investigator per revised International Working Group (IWG) AML criteria. HR-MDS: the number of participants with CR, PR, marrow CR (mCR), or hematologic improvement (HI) determined by the investigator per revised IWG MDS criteria.
Measured in the response evaluable population, which included participants who completed 1 cycle of study treatment, and had a follow-up assessment of disease status, and did not have any major protocol violations, or withdrew from the study before completion of Cycle 1 because of documented disease progression. Overall Number of Participants analyzed (N) signifies those who were evaluable for this Endpoint.

End point type	Primary

End point timeframe:

Up to 48 months

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Data is presented as specified in the statistical analysis plan.

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No statistical analyses were planned for this endpoint.

End point values	R/R Non-APL AML or R/R HR-MDS: Tamibarotene Monotherapy	Newly Diagnosed Non-APL AML: Tamibarotene Monotherapy	R/R non-APL AML: Tamibarotene and Azacitidine	ND Non-APL AML: Tamibarotene and Azacitidine: RARA-Positive
Subject group type	Reporting group	Reporting group	Reporting group	Subject analysis set
Number of subjects analysed	22	2	21	18
Units: Participants	2	0	4	12

Statistical analyses

No statistical analyses for this end point

Primary: Transfusion Independence Rate (TIR) in LR-MDS Participants Treated With Tamibarotene Monotherapy

End point title	Transfusion Independence Rate (TIR) in LR-MDS Participants Treated With Tamibarotene Monotherapy[3][4]

End point description:

TIR was defined as the number of participants who achieved transfusion independence defined as 8 consecutive weeks of red blood cell (RBC) transfusion independence.
Measured in the population evaluable for TIR, which included all participants who received at least 8 weeks of study treatment.
Here, Overall Number of Participants analyzed (N) signifies those who were evaluable for this Endpoint.

End point type	Primary

End point timeframe:

Up to 48 months

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were planned for this endpoint.

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Data is presented as specified in the statistical analysis plan.

End point values	LR-MDS: Tamibarotene Monotherapy			
Subject group type	Reporting group			
Number of subjects analysed	27			
Units: Participants	0			

Statistical analyses

No statistical analyses for this end point

Primary: Number of Participants with Treatment-emergent Adverse Events (TEAEs) Treated With Tamibarotene in Combination With Daratumumab

End point title	Number of Participants with Treatment-emergent Adverse Events (TEAEs) Treated With Tamibarotene in Combination With Daratumumab[5][6]

End point description:

A TEAE was any untoward medical occurrence associated with use of a study drug/study participation, whether or not considered related to study drug after first dose. A TEAE was any unfavorable/unintended sign (including abnormal laboratory finding), symptom, or disease temporally associated with the study drug. A serious TEAE resulted in death, was life-threatening, required inpatient hospitalization/prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect in the offspring of a participant who received study drug or other important medical events. Measured in the safety population, which included all screened participants who received any amount of study drug (tamibarotene or combination treatment). A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

End point type	Primary

End point timeframe:

Up to 48 months

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were planned for this endpoint.

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Data is presented as specified in the statistical analysis plan

End point values	R/R non-APL AML or R/R HR-MDS: Tamibarotene and Daratumumab			
Subject group type	Reporting group			
Number of subjects analysed	16			
Units: Participants				
TEAE	16			

Treatment-emergent SAE	12			

Statistical analyses

No statistical analyses for this end point

Secondary: ORR in AML Participants Positive for the RARA Super-enhancer Associated Biomarker Treated With Tamibarotene Combination With Azacitidine

End point title	ORR in AML Participants Positive for the RARA Super-enhancer Associated Biomarker Treated With Tamibarotene Combination With Azacitidine[7]

End point description:

ORR was defined as: AML: the number of participants with CR, CRi, CRh, PR, or MLFS as determined by the investigator per the revised IWG AML criteria.
Measured in the response evaluable population (which included participants who completed 1 cycle of study treatment, and had a follow-up assessment of disease status, and did not have any major protocol violations, or withdrew from the study before completion of Cycle 1 because of documented disease progression) in participants who were RARA-positive. Here, Overall Number of Participants analyzed (N) signifies those who were evaluable for this Endpoint.

End point type	Secondary

End point timeframe:

Up to 48 months

Notes:

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Per prespecified analysis, data were not collected for this Endpoint for the "R/R Non-APL AML or R/R HR-MDS: Tamibarotene Monotherapy" arm, the "Newly Diagnosed Non-APL AML: Tamibarotene Monotherapy" arm, and the "R/R non-APL AML or R/R HR-MDS: Tamibarotene and Daratumumab" arm as there were fewer than 5 responders per arm. Data are presented per specifications in the statistical analysis plan.

End point values	R/R non-APL AML: Tamibarotene and Azacitidine	ND Non-APL AML: Tamibarotene and Azacitidine: RARA-Positive		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	21	18		
Units: Participants	4	12		

Statistical analyses

No statistical analyses for this end point

Secondary: ORR in AML Participants Positive for the Interferon Regulatory Factor 8 (IRF8) Biomarker and Negative for the RARA Super-enhancer Associated Biomarker Treated With Tamibarotene in Combination With Azacitidine

End point title	ORR in AML Participants Positive for the Interferon Regulatory Factor 8 (IRF8) Biomarker and Negative for the RARA Super-enhancer Associated Biomarker Treated With Tamibarotene in

	Combination With Azacitidine[8]

End point description:

ORR was defined as: AML: number of participants with CR, CRi, CRh, PR, or MLFS determined by the investigator per the revised IWG AML criteria.
Measured in the response evaluable population (which included participants who completed 1 cycle of study treatment, had a follow-up assessment of disease status, did not have any major protocol violations, or withdrew from the study before completion of Cycle 1 because of documented disease progression) in participants who were positive for the IRF8 biomarker and negative for the RARA super-enhancer associated biomarker. Here, Overall Number of Participants analyzed (N) signifies those who were evaluable for this Endpoint.

End point type	Secondary

End point timeframe:

Up to 48 months

Notes:

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Per prespecified analysis, data were collected for this Endpoint only for the arm that enrolled the IRF8-positive participants and that included 5 or more responders. Data are presented per specifications in the statistical analysis plan.

End point values	Newly Diagnosed Non-APL AML: Tamibarotene and Azacitidine			
Subject group type	Reporting group			
Number of subjects analysed	4			
Units: Participants	2			

Statistical analyses

No statistical analyses for this end point

Secondary: ORR in AML Participants Negative for the RARA Super-enhancer Associated Biomarker Treated With Tamibarotene Combination With Azacitidine

End point title	ORR in AML Participants Negative for the RARA Super-enhancer Associated Biomarker Treated With Tamibarotene Combination With Azacitidine

End point description:

ORR was defined as:
AML: the number of participants with CR, CRi, CRh, PR, or MLFS as determined by the investigator per the revised IWG AML criteria.
Measured in the response evaluable population, which included participants who completed 1 cycle of study treatment, and had a follow-up assessment of disease status, and did not have any major protocol violations, or withdrew from the study before completion of Cycle 1 because of documented disease progression. Here, Overall Number of Participants analyzed (N) signifies those who were evaluable for this Endpoint. Per prespecified analysis, data were collected for this Endpoint only for the arm that enrolled the RARA-negative participants and that included 5 or more responders. Data are presented per specifications in the statistical analysis plan.

End point type	Secondary

End point timeframe:

Up to 48 months

End point values	ND Non-APL AML: Tamibarotene and Azacitidine: RARA-Negative			
Subject group type	Subject analysis set			
Number of subjects analysed	28			
Units: Participants	12			

Statistical analyses

No statistical analyses for this end point

Secondary: ORR for AML or HR-MDS Participants Treated With Tamibarotene in Combination With Daratumumab

End point title	ORR for AML or HR-MDS Participants Treated With Tamibarotene in Combination With Daratumumab[9]

End point description:

ORR was defined as:
AML: the number of participants with CR, CRi, CRh, PR, or MLFS as determined by the investigator per the revised IWG AML criteria.
HR-MDS: the number of participants with CR, PR, mCR, or HI as determined by the investigator per the revised IWG MDS criteria.
Measured in the response evaluable population (which included participants who completed 1 cycle of study treatment, and had a follow-up assessment of disease status, and did not have any major protocol violations, or withdrew from the study before completion of Cycle 1 because of documented disease progression) who had evaluable data for the endpoint.

End point type	Secondary

End point timeframe:

Up to 48 months

Notes:

[9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Data is presented as specified in the statistical analysis plan.

End point values	R/R non-APL AML or R/R HR-MDS: Tamibarotene and Daratumumab			
Subject group type	Reporting group			
Number of subjects analysed	12			
Units: Participants	2			

Statistical analyses

No statistical analyses for this end point

Secondary: Event-Free Survival (EFS) in AML and HR-MDS Participants Treated With Tamibarotene in Combination With Azacitidine

End point title	Event-Free Survival (EFS) in AML and HR-MDS Participants Treated With Tamibarotene in Combination With Azacitidine[10]

End point description:

EFS was defined as time from first treatment until date of documentation of disease relapse following CR, CRi, or death, whichever occurred first. If the participant did not achieve a CR, EFS was defined as the point of progression or death, whichever occurred first.
Measured in the safety population, which included all screened participants who received any amount of study drug (tamibarotene or combination treatment). Here, Overall Number of Participants analyzed (N) signifies those who were evaluable for this Endpoint.

End point type	Secondary

End point timeframe:

Up to 48 months

Notes:

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Per prespecified analysis, data were not collected for the Non-APL AML: Tamibarotene Monotherapy arm as there were fewer than 5 participants in the arm. Data are presented per specifications in the statistical analysis plan.

End point values	R/R Non-APL AML or R/R HR-MDS: Tamibarotene Monotherapy	R/R non-APL AML: Tamibarotene and Azacitidine	R/R non-APL AML or R/R HR-MDS: Tamibarotene and Daratumumab	ND Non-APL AML: Tamibarotene and Azacitidine: RARA-Positive
Subject group type	Reporting group	Reporting group	Reporting group	Subject analysis set
Number of subjects analysed	29	28	16	22
Units: months				
median (confidence interval 95%)	2.6 (1.2 to 2.8)	3.3 (1.9 to 5.5)	1.2 (1.1 to 2.1)	8.3 (3.1 to 11.8)

Statistical analyses

No statistical analyses for this end point

Secondary: Duration of Response (DOR) in AML Participants Treated With Tamibarotene in Combination With Azacitidine

End point title	Duration of Response (DOR) in AML Participants Treated With Tamibarotene in Combination With Azacitidine[11]

End point description:

DOR was defined as time from first date of response CR, CRi, CRh, MLFS or PR until the date of relapse. 99999 = upper confidence interval was not estimable.
Measured in the response evaluable population, which included participants who completed 1 cycle of study treatment, and had a follow-up assessment of disease status, and did not have any major protocol violations, or withdrew from the study before completion of Cycle 1 because of documented disease progression. Here, Overall Number of Participants analyzed (N) signifies those who were evaluable for this Endpoint.

End point type	Secondary

End point timeframe:

Up to 48 months

Notes:

[11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Justification: As prespecified, analysis of DOR was not performed for any of the

Tamibarotene Monotherapy arms, or R/R non-APL AML or R/R HR-MDS: Tamibarotene and Daratumumab arm, as there were fewer than 5 responders in those study arms. Data is presented as specified in the statistical analysis plan.

End point values	R/R non-APL AML: Tamibarotene and Azacitidine	ND Non-APL AML: Tamibarotene and Azacitidine: RARA-Positive		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	21	18		
Units: months				
median (confidence interval 95%)	5.9 (1.0 to 99999)	10.8 (2.9 to 99999)		

Statistical analyses

No statistical analyses for this end point

Secondary: Overall Survival (OS) in AML and HR-MDS Participants Treated With Tamibarotene Monotherapy, or in Combination With Azacitidine or Daratumumab

End point title	Overall Survival (OS) in AML and HR-MDS Participants Treated With Tamibarotene Monotherapy, or in Combination With Azacitidine or Daratumumab[12]

End point description:

OS was defined as the time from first treatment until death from any cause.
Measured in the safety population, which included all screened participants who received any amount of study drug (tamibarotene or combination treatment). Here, Overall Number of Participants analyzed (N) signifies those who were evaluable for this Endpoint.

End point type	Secondary

End point timeframe:

Up to 48 months

Notes:

[12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Per planned analysis, data was not collected for LR-MDS: Tamibarotene Monotherapy arm for this Endpoint and analysis of OS was not performed for Newly Diagnosed Non-APL AML: Tamibarotene Monotherapy as there were fewer than 5 participants in this study arm. All-cause mortality is reported in the Reported Adverse Events module. Data is presented as specified in the statistical analysis plan.

End point values	R/R Non-APL AML or R/R HR-MDS: Tamibarotene Monotherapy	R/R non-APL AML: Tamibarotene and Azacitidine	R/R non-APL AML or R/R HR-MDS: Tamibarotene and Daratumumab	ND Non-APL AML: Tamibarotene and Azacitidine: RARA-Positive
Subject group type	Reporting group	Reporting group	Reporting group	Subject analysis set
Number of subjects analysed	29	28	16	22
Units: months				
median (confidence interval 95%)	5.7 (2.7 to 7.1)	5.9 (2.7 to 11.0)	3.6 (1.8 to 4.6)	11.7 (6.6 to 15.8)

Statistical analyses

No statistical analyses for this end point

Secondary: Hematologic Improvement (HI) in AML, HR-MDS and LR-MDS Participants Treated With Tamibarotene Monotherapy, or in Combination With Azacitidine or Daratumumab

End point title	Hematologic Improvement (HI) in AML, HR-MDS and LR-MDS Participants Treated With Tamibarotene Monotherapy, or in Combination With Azacitidine or Daratumumab[13]

End point description:

HI was defined according to the modified IWG response criteria for MDS as the number of participants with a response (lasting at least 8 weeks) after first treatment, including erythroid response, platelet response, or neutrophil response.
Measured in the population evaluable for HI, which included all participants who received at least 8 weeks of study treatment.
Here, Overall Number of Participants analyzed (N) signifies those who were evaluable for this Endpoint.

End point type	Secondary

End point timeframe:

Up to 48 months

Notes:

[13] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Data is presented as specified in the statistical analysis plan.

End point values	R/R Non-APL AML or R/R HR-MDS: Tamibarotene Monotherapy	Newly Diagnosed Non-APL AML: Tamibarotene Monotherapy	LR-MDS: Tamibarotene Monotherapy	R/R non-APL AML: Tamibarotene and Azacitidine
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	16	2	25	17
Units: Participants	3	0	1	1

End point values	R/R non-APL AML or R/R HR-MDS: Tamibarotene and Daratumumab	ND Non-APL AML: Tamibarotene and Azacitidine: RARA-Positive		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	9	16		
Units: Participants	0	4		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants with TEAEs Number of Participants with Adverse Events in AML and MDS participants treated with tamibarotene monotherapy or in combination with azacitidine

End point title	Number of Participants with TEAEs Number of Participants with Adverse Events in AML and MDS participants treated with tamibarotene monotherapy or in combination with azacitidine[14]

End point description:

A TEAE was any untoward medical occurrence associated with use of a study drug/study participation, whether or not considered related to study drug after first dose. A TEAE was any unfavorable/unintended sign (including abnormal laboratory finding), symptom, or disease temporally associated with the study drug. A serious TEAE resulted in death, was life-threatening, required inpatient hospitalization/prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect in the offspring of a participant who received study drug or other important medical events. Measured in the safety population, which included all screened participants who received any amount of study drug (tamibarotene or combination treatment). A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

End point type	Secondary

End point timeframe:

Up to 48 months

Notes:

[14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Data is presented as specified in the statistical analysis plan.

End point values	R/R Non-APL AML or R/R HR-MDS: Tamibarotene Monotherapy	Newly Diagnosed Non-APL AML: Tamibarotene Monotherapy	LR-MDS: Tamibarotene Monotherapy	Newly Diagnosed Non-APL AML: Tamibarotene and Azacitidine
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	29	2	29	51
Units: Participants				
TEAE	29	2	29	51
Treatment-emergent SAE	16	2	15	43

End point values	R/R non-APL AML: Tamibarotene and Azacitidine			
Subject group type	Reporting group			
Number of subjects analysed	28			
Units: Participants				
TEAE	27			
Treatment-emergent SAE	20			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Up to 48 months

Adverse event reporting additional description:

Measured in the safety population, which included all screened participants who received any amount of study drug (tamibarotene or combination treatment).

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	19

Reporting groups

Reporting group title	R/R Non-APL AML or R/R HR-MDS: Tamibarotene Monotherapy

Reporting group description:

Participants with R/R non-APL AML or R/R HR-MDS received tamibarotene at 6 mg/m^2/day in 2 divided doses on Days 1-28 of a 28-day cycle.

Reporting group title	Newly Diagnosed Non-APL AML: Tamibarotene Monotherapy

Reporting group description:

Newly diagnosed, treatment-naive participants with non-APL AML who were unlikely to tolerate standard intensive chemotherapy received tamibarotene at 6 mg/m^2/day in 2 divided doses on Days 1-28 of a 28-day cycle.

Reporting group title	LR-MDS: Tamibarotene Monotherapy

Reporting group description:

Participants with transfusion-dependent lower-risk myelodysplastic syndrome (LR-MDS) without the del-5q abnormality who were refractory to erythropoietin (EPO) treatment or unlikely to respond to EPO treatment received tamibarotene at 6 mg/m^2/day in 2 divided doses from Days 1-28 of a 28-day cycle

Reporting group title	Newly Diagnosed Non-APL AML: Tamibarotene and Azacitidine

Reporting group description:

Newly diagnosed, treatment-naive participants with non-APL AML who were unlikely to tolerate standard intensive chemotherapy received tamibarotene at 6 mg/m^2/day in 2 divided doses on Days 8-28 of a 28-day cycle, and azacitidine at 75 mg/m^2 once daily on Days 1-7 of a 28-day cycle

This arm included both RARA-positive and RARA-negative participants with newly diagnosed Non-APL AML treated with tamibarotene and azacitidine.

Reporting group title	R/R non-APL AML: Tamibarotene and Azacitidine

Reporting group description:

Participants with R/R non-APL AML received tamibarotene from Days 8-28 of a 28-day cycle, and azacitidine on Days 1-7 of a 28-day cycle.

Reporting group title	R/R non-APL AML or R/R HR-MDS: Tamibarotene and Daratumumab

Reporting group description:

Participants with R/R non-APL AML or R/R HR-MDS received tamibarotene during a 7-day lead-in and on Days 1-28 of a 28-day cycle. Participants also received daratumumab on Cycle 1 Day 1 weekly for 8 weeks, followed by dosing every 2 weeks for 16 weeks, followed by dosing every 4 weeks.

Serious adverse events	R/R Non-APL AML or R/R HR-MDS: Tamibarotene Monotherapy	Newly Diagnosed Non-APL AML: Tamibarotene Monotherapy	LR-MDS: Tamibarotene Monotherapy
Total subjects affected by serious adverse events			
subjects affected / exposed	16 / 29 (55.17%)	2 / 2 (100.00%)	15 / 29 (51.72%)

number of deaths (all causes) number of deaths resulting from adverse events	23	2	3
Vascular disorders			
Orthostatic hypotension			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Deep vein thrombosis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vasculitis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple organ dysfunction syndrome			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical health deterioration			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			

Postmenopausal haemorrhage			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Hypoxia			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	2 / 29 (6.90%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary granuloma			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute respiratory distress syndrome			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemoptysis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Lung disorder			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory distress			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Delirium			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mental status changes			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Blood bilirubin increased			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Fall			

subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	3 / 29 (10.34%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Overdose			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural haematoma			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femur fracture			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Cardiac failure congestive			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac arrest			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myocardial infarction			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina pectoris			

subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina unstable			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiomyopathy			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cranial nerve disorder			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dizziness			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hydrocephalus			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neuralgia			

subjects affected / exposed	0 / 29 (0.00%)	1 / 2 (50.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral haemorrhage			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lacunar stroke			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Partial seizures			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sciatica			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			

subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile neutropenia			
subjects affected / exposed	6 / 29 (20.69%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 8	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancytopenia			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukocytosis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukostasis syndrome			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphopenia			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Constipation			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysphagia			

subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enteritis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenic colitis			

subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal haemorrhage			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stomatitis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholecystitis acute			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholelithiasis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Dermatitis allergic			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Renal failure			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal injury			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urethral stenosis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	2 / 29 (6.90%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone pain			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscle haemorrhage			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain in extremity			
subjects affected / exposed	0 / 29 (0.00%)	1 / 2 (50.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthralgia			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Flank pain			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Groin pain			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal pain			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Infection			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung infection			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pharyngeal abscess			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	4 / 29 (13.79%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia fungal			
subjects affected / exposed	0 / 29 (0.00%)	1 / 2 (50.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Pneumonia parainfluenzae viral			

subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia staphylococcal			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pseudomonal sepsis			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	2 / 29 (6.90%)	0 / 2 (0.00%)	3 / 29 (10.34%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Septic shock			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Urinary tract infection			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound infection			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacteraemia			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			

subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Klebsiella bacteraemia			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pseudomonas infection			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary mycosis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthritis infective			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atypical pneumonia			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			

subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterobacter pneumonia			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erysipelas			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia bacteraemia			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung abscess			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malaria			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nocardiosis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oral candidiasis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Proteus infection			

subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Serratia sepsis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin infection			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal infection			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Streptococcal bacteraemia			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	2 / 29 (6.90%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperkalaemia			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lactic acidosis			

subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Failure to thrive			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Decreased appetite			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gout			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypercalcaemia			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertriglyceridaemia			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Newly Diagnosed Non-APL AML: Tamibarotene and Azacitidine	R/R non-APL AML: Tamibarotene and Azacitidine	R/R non-APL AML or R/R HR-MDS: Tamibarotene and Daratumumab
Total subjects affected by serious adverse events			
subjects affected / exposed	43 / 51 (84.31%)	20 / 28 (71.43%)	12 / 16 (75.00%)
number of deaths (all causes)	43	24	15
number of deaths resulting from adverse events			
Vascular disorders			
Orthostatic hypotension			

subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Deep vein thrombosis			
subjects affected / exposed	2 / 51 (3.92%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vasculitis			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	5 / 51 (9.80%)	1 / 28 (3.57%)	1 / 16 (6.25%)
occurrences causally related to treatment / all	1 / 5	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple organ dysfunction syndrome			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Fatigue			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical health deterioration			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Postmenopausal haemorrhage			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Respiratory, thoracic and mediastinal disorders			
Hypoxia			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary granuloma			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	2 / 16 (12.50%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Acute respiratory distress syndrome			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemoptysis			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung disorder			
subjects affected / exposed	2 / 51 (3.92%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Pleural effusion			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis			
subjects affected / exposed	1 / 51 (1.96%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Respiratory distress			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Delirium			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mental status changes			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Blood bilirubin increased			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Overdose			

subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural haematoma			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femur fracture			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Cardiac failure congestive			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac arrest			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Cardiac failure			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myocardial infarction			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina pectoris			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina unstable			

subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiomyopathy			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	2 / 51 (3.92%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cranial nerve disorder			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dizziness			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hydrocephalus			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neuralgia			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			

subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral haemorrhage			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Cerebrovascular accident			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lacunar stroke			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Partial seizures			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sciatica			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile neutropenia			

subjects affected / exposed	12 / 51 (23.53%)	9 / 28 (32.14%)	7 / 16 (43.75%)
occurrences causally related to treatment / all	1 / 13	1 / 11	0 / 9
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Pancytopenia			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukocytosis			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukostasis syndrome			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphopenia			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Constipation			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysphagia			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			

subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enteritis			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenic colitis			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			

subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal haemorrhage			
subjects affected / exposed	1 / 51 (1.96%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stomatitis			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholecystitis acute			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholelithiasis			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Dermatitis allergic			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	2 / 51 (3.92%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Renal injury			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urethral stenosis			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone pain			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscle haemorrhage			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain in extremity			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthralgia			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Flank pain			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Groin pain			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal pain			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Infection			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung infection			
subjects affected / exposed	2 / 51 (3.92%)	1 / 28 (3.57%)	1 / 16 (6.25%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pharyngeal abscess			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	8 / 51 (15.69%)	3 / 28 (10.71%)	3 / 16 (18.75%)
occurrences causally related to treatment / all	1 / 9	0 / 3	1 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia fungal			
subjects affected / exposed	1 / 51 (1.96%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Pneumonia parainfluenzae viral			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia staphylococcal			

subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pseudomonal sepsis			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	5 / 51 (9.80%)	4 / 28 (14.29%)	3 / 16 (18.75%)
occurrences causally related to treatment / all	0 / 5	1 / 6	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 2	0 / 0
Septic shock			
subjects affected / exposed	2 / 51 (3.92%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	1 / 51 (1.96%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound infection			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacteraemia			
subjects affected / exposed	1 / 51 (1.96%)	1 / 28 (3.57%)	1 / 16 (6.25%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			

subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	1 / 16 (6.25%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Klebsiella bacteraemia			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pseudomonas infection			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary mycosis			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Arthritis infective			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atypical pneumonia			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterobacter pneumonia			

subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erysipelas			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia bacteraemia			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung abscess			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Malaria			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Nocardiosis			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oral candidiasis			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Proteus infection			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			

subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Serratia sepsis			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin infection			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal infection			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Streptococcal bacteraemia			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperkalaemia			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lactic acidosis			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Failure to thrive			

subjects affected / exposed	1 / 51 (1.96%)	1 / 28 (3.57%)	2 / 16 (12.50%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Decreased appetite			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gout			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypercalcaemia			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertriglyceridaemia			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	R/R Non-APL AML or R/R HR-MDS: Tamibarotene Monotherapy	Newly Diagnosed Non-APL AML: Tamibarotene Monotherapy	LR-MDS: Tamibarotene Monotherapy
Total subjects affected by non-serious adverse events			
subjects affected / exposed	29 / 29 (100.00%)	2 / 2 (100.00%)	29 / 29 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Fibrous histiocytoma			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Superficial spreading melanoma stage unspecified			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1

Anal cancer			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Endometrial cancer			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Squamous cell carcinoma of skin			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			
Pallor			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	2
Vascular insufficiency			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Venous thrombosis			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Hypertension			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Hypotension			
subjects affected / exposed	2 / 29 (6.90%)	0 / 2 (0.00%)	2 / 29 (6.90%)
occurrences (all)	2	0	2
Deep vein thrombosis			
subjects affected / exposed	2 / 29 (6.90%)	0 / 2 (0.00%)	3 / 29 (10.34%)
occurrences (all)	2	0	3
Haematoma			
subjects affected / exposed	0 / 29 (0.00%)	2 / 2 (100.00%)	0 / 29 (0.00%)
occurrences (all)	0	2	0
Thrombophlebitis superficial			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Thrombosis			

subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Hot flush			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	2	0	0
Erythema			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	2 / 29 (6.90%)
occurrences (all)	1	0	2
Surgical and medical procedures			
Shoulder arthroplasty			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Adverse drug reaction			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Asthenia			
subjects affected / exposed	4 / 29 (13.79%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	4	0	1
Catheter site erythema			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Catheter site pain			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Chills			
subjects affected / exposed	4 / 29 (13.79%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	4	0	1
Crepitations			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Device related thrombosis			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Exercise tolerance decreased			

subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Facial pain			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	2 / 29 (6.90%)
occurrences (all)	0	0	2
Fatigue			
subjects affected / exposed	12 / 29 (41.38%)	0 / 2 (0.00%)	9 / 29 (31.03%)
occurrences (all)	13	0	9
Gait disturbance			
subjects affected / exposed	0 / 29 (0.00%)	1 / 2 (50.00%)	1 / 29 (3.45%)
occurrences (all)	0	1	1
Injection site bruising			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	1	0	1
Injection site haemorrhage			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Malaise			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	3 / 29 (10.34%)
occurrences (all)	1	0	3
Medical device pain			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Medical device site erythema			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Oedema peripheral			
subjects affected / exposed	8 / 29 (27.59%)	1 / 2 (50.00%)	5 / 29 (17.24%)
occurrences (all)	12	1	6
Pain			
subjects affected / exposed	2 / 29 (6.90%)	0 / 2 (0.00%)	2 / 29 (6.90%)
occurrences (all)	2	0	2
Pyrexia			
subjects affected / exposed	8 / 29 (27.59%)	0 / 2 (0.00%)	3 / 29 (10.34%)
occurrences (all)	8	0	3
Catheter site rash			

subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Chest pain			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
General physical health deterioration			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Impaired healing			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Inflammatory pain			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Injection site erythema			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Injection site irritation			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Injection site nodule			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Injection site pain			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Injection site reaction			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Localised oedema			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Mucosal inflammation			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Non-cardiac chest pain			

subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Peripheral swelling			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Systemic inflammatory response syndrome			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Catheter site swelling			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Early satiety			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Immune system disorders			
Acute graft versus host disease			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			
Pelvic pain			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Vulvovaginal pain			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Ovarian vein thrombosis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Perineal pain			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Postmenopausal haemorrhage			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Vaginal haemorrhage			

subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Bronchiectasis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Cough			
subjects affected / exposed	7 / 29 (24.14%)	1 / 2 (50.00%)	4 / 29 (13.79%)
occurrences (all)	7	1	4
Dyspnoea			
subjects affected / exposed	8 / 29 (27.59%)	0 / 2 (0.00%)	2 / 29 (6.90%)
occurrences (all)	8	0	2
Dyspnoea exertional			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Epistaxis			
subjects affected / exposed	3 / 29 (10.34%)	1 / 2 (50.00%)	2 / 29 (6.90%)
occurrences (all)	3	1	2
Hypopnoea			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Hypoxia			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	3 / 29 (10.34%)
occurrences (all)	0	0	3
Lung disorder			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Nasal congestion			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	3 / 29 (10.34%)
occurrences (all)	1	0	3
Nasal dryness			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Oropharyngeal pain			

subjects affected / exposed	2 / 29 (6.90%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	2	0	1
Pleural effusion			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Productive cough			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Rales			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	2 / 29 (6.90%)
occurrences (all)	0	0	2
Rhonchi			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Sneezing			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Upper-airway cough syndrome			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	2 / 29 (6.90%)
occurrences (all)	0	0	2
Wheezing			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Tachypnoea			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Tonsillar hypertrophy			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Acute promyelocytic leukaemia differentiation syndrome			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Acute pulmonary oedema			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0

Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Dysphonia			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Laryngeal haemorrhage			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Lung consolidation			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Pleuritic pain			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Pulmonary embolism			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Pulmonary mass			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Pulmonary oedema			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Respiratory acidosis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Respiratory distress			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Respiratory failure			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Rhinorrhoea			

subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Haemoptysis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Pneumothorax			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Nasal mucosal ulcer			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Laryngospasm			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Anxiety			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Confusional state			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	2 / 29 (6.90%)
occurrences (all)	0	0	3
Delirium			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Depression			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	3 / 29 (10.34%)
occurrences (all)	1	0	3
Hallucination			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Insomnia			
subjects affected / exposed	2 / 29 (6.90%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	3	0	2
Hallucination, Visual acuity reduced			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0

Mental status changes			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Panic attack			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Psychomotor retardation			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Genito-pelvic pain/penetration disorder			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Hallucination, Olfactory			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Investigations			
Activated partial thromboplastin time prolonged			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	3 / 29 (10.34%)
occurrences (all)	0	0	4
Alanine aminotransferase increased			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	4	0	1
Amylase increased			
subjects affected / exposed	2 / 29 (6.90%)	1 / 2 (50.00%)	0 / 29 (0.00%)
occurrences (all)	2	6	0
Aspartate aminotransferase increased			
subjects affected / exposed	2 / 29 (6.90%)	0 / 2 (0.00%)	2 / 29 (6.90%)
occurrences (all)	2	0	3
Blood cholesterol increased			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	1	0	1
Blood creatinine increased			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	3 / 29 (10.34%)
occurrences (all)	1	0	3
Blood phosphorus decreased			

subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Blood thyroid stimulating hormone increased			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Blood triglycerides increased			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Breath sounds abnormal			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Cardiac murmur			
subjects affected / exposed	2 / 29 (6.90%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	2	0	0
Ejection fraction decreased			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
High density lipoprotein decreased			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
International normalised ratio increased			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	3 / 29 (10.34%)
occurrences (all)	0	0	3
Lipase decreased			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Lipase increased			
subjects affected / exposed	2 / 29 (6.90%)	0 / 2 (0.00%)	2 / 29 (6.90%)
occurrences (all)	2	0	5
Neutrophil count decreased			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	4 / 29 (13.79%)
occurrences (all)	1	0	9
Platelet count decreased			

subjects affected / exposed	3 / 29 (10.34%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	6	0	1
Respiratory rate increased			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Skin turgor decreased			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Vitamin K decreased			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Weight decreased			
subjects affected / exposed	6 / 29 (20.69%)	1 / 2 (50.00%)	6 / 29 (20.69%)
occurrences (all)	12	2	6
White blood cell count decreased			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	3 / 29 (10.34%)
occurrences (all)	1	0	5
Blood bilirubin increased			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Blood uric acid increased			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Coronavirus test positive			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Electrocardiogram QT prolonged			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Respiratory syncytial virus test positive			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Troponin I increased			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0

Blood alkaline phosphatase increased			
subjects affected / exposed	2 / 29 (6.90%)	0 / 2 (0.00%)	5 / 29 (17.24%)
occurrences (all)	2	0	5
Chest X-ray abnormal			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Heart rate irregular			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Lymphocyte count decreased			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	3 / 29 (10.34%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	3	0	1
Excoriation			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Eye injury			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Fall			
subjects affected / exposed	4 / 29 (13.79%)	0 / 2 (0.00%)	4 / 29 (13.79%)
occurrences (all)	5	0	6
Joint dislocation			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Laceration			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	1	0	1
Post procedural haematoma			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Rib fracture			

subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Scratch			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Animal bite			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Eschar			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Face injury			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Lumbar vertebral fracture			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Procedural pain			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Procedural site reaction			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Road traffic accident			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Transfusion reaction			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Transfusion-related circulatory overload			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Wrist fracture			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0

Infusion related reaction			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Periorbital haemorrhage			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Skin abrasion			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Thermal burn			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Congenital, familial and genetic disorders			
Macroglossia			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Angina pectoris			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Atrial fibrillation			
subjects affected / exposed	2 / 29 (6.90%)	0 / 2 (0.00%)	2 / 29 (6.90%)
occurrences (all)	2	0	2
Atrial flutter			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	2	0	0
Atrial tachycardia			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Bradycardia			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Nodal rhythm			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Palpitations			

subjects affected / exposed	2 / 29 (6.90%)	0 / 2 (0.00%)	2 / 29 (6.90%)
occurrences (all)	3	0	2
Sinus bradycardia			
subjects affected / exposed	0 / 29 (0.00%)	1 / 2 (50.00%)	0 / 29 (0.00%)
occurrences (all)	0	1	0
Sinus tachycardia			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Tachycardia			
subjects affected / exposed	3 / 29 (10.34%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	3	0	0
Angina unstable			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Cardiac arrest			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Cardiac failure			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Cardiomyopathy			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Coronary artery insufficiency			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Left ventricular dysfunction			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Pericardial effusion			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Ventricular hypokinesia			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Pericarditis			

subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Cerebrovascular accident			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Cognitive disorder			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Cranial nerve disorder			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Disturbance in attention			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Dizziness			
subjects affected / exposed	9 / 29 (31.03%)	1 / 2 (50.00%)	1 / 29 (3.45%)
occurrences (all)	10	3	1
Dizziness postural			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Dysgeusia			
subjects affected / exposed	3 / 29 (10.34%)	0 / 2 (0.00%)	3 / 29 (10.34%)
occurrences (all)	3	0	3
Encephalopathy			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Facial paresis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Haemorrhage intracranial			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Headache			
subjects affected / exposed	5 / 29 (17.24%)	1 / 2 (50.00%)	2 / 29 (6.90%)
occurrences (all)	5	1	3

Memory impairment			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	1	0	1
Neuropathy peripheral			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Paraesthesia			
subjects affected / exposed	2 / 29 (6.90%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	2	0	1
Peripheral sensory neuropathy			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Presyncope			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Seizure			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Sinus headache			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Speech disorder			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Syncope			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Tongue paralysis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Tremor			
subjects affected / exposed	2 / 29 (6.90%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	2	0	0
Ageusia			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0

Akathisia			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Ataxia			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Balance disorder			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Carotid artery thrombosis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Coordination abnormal			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Nerve compression			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Cerebellar syndrome			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Epilepsy			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Hyperaesthesia			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Hypogeusia			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Lethargy			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Parkinson's disease			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0

Parkinsonism			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Partial seizures			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Sciatica			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Somnolence			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	6 / 29 (20.69%)	0 / 2 (0.00%)	2 / 29 (6.90%)
occurrences (all)	12	0	4
Febrile neutropenia			
subjects affected / exposed	6 / 29 (20.69%)	0 / 2 (0.00%)	2 / 29 (6.90%)
occurrences (all)	12	0	4
Increased tendency to bruise			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Lymphadenopathy			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Neutropenia			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	2	0	2
Splenic lesion			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Thrombocytopenia			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	2 / 29 (6.90%)
occurrences (all)	1	0	4
Disseminated intravascular coagulation			

subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Leukopenia			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Lymph node pain			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Lymphopenia			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Splenomegaly			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Thrombocytopenic purpura			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Thymus disorder			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
Ear discomfort			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Ear pain			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Excessive cerumen production			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
External ear pain			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Hypoacusis			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	2	0	1

Mastoid effusion			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Cerumen impaction			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Deafness unilateral			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Vertigo			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
Cataract			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Conjunctival haemorrhage			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Dry eye			
subjects affected / exposed	2 / 29 (6.90%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	2	0	0
Eye disorder			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Eye irritation			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Eye pain			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Retinal haemorrhage			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Retinal vascular disorder			

subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Vision blurred			
subjects affected / exposed	3 / 29 (10.34%)	1 / 2 (50.00%)	0 / 29 (0.00%)
occurrences (all)	3	1	0
Exophthalmos			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Ocular hyperaemia			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Photophobia			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Blindness			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 29 (0.00%)	1 / 2 (50.00%)	0 / 29 (0.00%)
occurrences (all)	0	1	0
Abdominal distension			
subjects affected / exposed	5 / 29 (17.24%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	5	0	0
Abdominal pain			
subjects affected / exposed	2 / 29 (6.90%)	0 / 2 (0.00%)	3 / 29 (10.34%)
occurrences (all)	2	0	3
Abdominal rigidity			
subjects affected / exposed	0 / 29 (0.00%)	1 / 2 (50.00%)	0 / 29 (0.00%)
occurrences (all)	0	1	0
Ascites			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Constipation			
subjects affected / exposed	2 / 29 (6.90%)	0 / 2 (0.00%)	4 / 29 (13.79%)
occurrences (all)	2	0	4

Diarrhoea			
subjects affected / exposed	8 / 29 (27.59%)	0 / 2 (0.00%)	4 / 29 (13.79%)
occurrences (all)	12	0	5
Dry mouth			
subjects affected / exposed	3 / 29 (10.34%)	1 / 2 (50.00%)	2 / 29 (6.90%)
occurrences (all)	3	1	2
Dyspepsia			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	3 / 29 (10.34%)
occurrences (all)	1	0	3
Dysphagia			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	2 / 29 (6.90%)
occurrences (all)	0	0	3
Flatulence			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Gastrooesophageal reflux disease			
subjects affected / exposed	2 / 29 (6.90%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	2	0	1
Gingival bleeding			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Haematochezia			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Lip dry			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Mouth ulceration			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Nausea			
subjects affected / exposed	4 / 29 (13.79%)	1 / 2 (50.00%)	4 / 29 (13.79%)
occurrences (all)	4	1	4

Oral pain			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Rectal ulcer			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Stomatitis			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Toothache			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	1	0	1
Vomiting			
subjects affected / exposed	3 / 29 (10.34%)	1 / 2 (50.00%)	4 / 29 (13.79%)
occurrences (all)	3	1	4
Abdominal pain upper			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Anal fissure			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Angina bullosa haemorrhagica			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Aphthous ulcer			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Faecaloma			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Gastritis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Haemorrhoids			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0

Inguinal hernia			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Lip swelling			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Melaena			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Mouth haemorrhage			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Noninfective gingivitis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Oral mucosal blistering			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Pancreatitis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Periodontal disease			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Proctalgia			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Rectal haemorrhage			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Tongue haematoma			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Lip haemorrhage			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0

Gingival pain			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Hepatobiliary disorders			
Cholelithiasis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	2 / 29 (6.90%)
occurrences (all)	0	0	2
Hyperbilirubinaemia			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Hepatic cirrhosis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	6 / 29 (20.69%)	1 / 2 (50.00%)	10 / 29 (34.48%)
occurrences (all)	7	1	14
Blister			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Cold sweat			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Dry skin			
subjects affected / exposed	5 / 29 (17.24%)	0 / 2 (0.00%)	2 / 29 (6.90%)
occurrences (all)	5	0	2
Hyperhidrosis			
subjects affected / exposed	2 / 29 (6.90%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	2	0	0
Night sweat			
subjects affected / exposed	3 / 29 (10.34%)	0 / 2 (0.00%)	2 / 29 (6.90%)
occurrences (all)	3	0	2
Onychomadesis			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Papule			

subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Petechiae			
subjects affected / exposed	6 / 29 (20.69%)	1 / 2 (50.00%)	2 / 29 (6.90%)
occurrences (all)	6	1	2
Pruritus			
subjects affected / exposed	4 / 29 (13.79%)	0 / 2 (0.00%)	4 / 29 (13.79%)
occurrences (all)	5	0	4
Purpura			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	1	0	1
Rash			
subjects affected / exposed	4 / 29 (13.79%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	6	0	1
Rash generalised			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Rash maculo-papular			
subjects affected / exposed	3 / 29 (10.34%)	0 / 2 (0.00%)	3 / 29 (10.34%)
occurrences (all)	6	0	3
Rash pruritic			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Skin discolouration			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Skin hyperpigmentation			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Skin induration			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	1	0	1
Skin lesion			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Skin mass			

subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Skin necrosis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Skin ulcer			
subjects affected / exposed	2 / 29 (6.90%)	0 / 2 (0.00%)	3 / 29 (10.34%)
occurrences (all)	3	0	4
Eczema			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Hyperkeratosis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Nodular rash			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Prurigo			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Pruritus generalised			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Pyoderma gangrenosum			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Rash erythematous			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Scab			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Skin erosion			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Skin exfoliation			

subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Stasis dermatitis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Sticky skin			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Urticaria			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Rash papular			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Chronic papillomatous dermatitis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Dermatitis psoriasiform			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Dermatitis bullous			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Drug eruption			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	2 / 29 (6.90%)
occurrences (all)	3	0	2
Chromaturia			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Dysuria			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0

Micturition urgency			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	1	0	1
Nocturia			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Pollakiuria			
subjects affected / exposed	0 / 29 (0.00%)	1 / 2 (50.00%)	2 / 29 (6.90%)
occurrences (all)	0	1	2
Proteinuria			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Urinary tract pain			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	2 / 29 (6.90%)
occurrences (all)	1	0	3
Urine odour abnormal			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Chronic kidney disease			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Haematuria			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Incontinence			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Urethral stenosis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Urinary hesitation			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Urinary incontinence			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0

Urinary retention			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Urine flow decreased			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Endocrine disorders			
Cushingoid			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Hypothyroidism			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	5 / 29 (17.24%)	1 / 2 (50.00%)	4 / 29 (13.79%)
occurrences (all)	7	1	5
Arthritis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Back pain			
subjects affected / exposed	4 / 29 (13.79%)	1 / 2 (50.00%)	4 / 29 (13.79%)
occurrences (all)	5	3	5
Bone pain			
subjects affected / exposed	0 / 29 (0.00%)	1 / 2 (50.00%)	1 / 29 (3.45%)
occurrences (all)	0	1	2
Bursitis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Groin pain			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Intervertebral disc protrusion			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	2	0	0
Joint range of motion decreased			

subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Muscle spasms			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Muscular weakness			
subjects affected / exposed	5 / 29 (17.24%)	0 / 2 (0.00%)	3 / 29 (10.34%)
occurrences (all)	6	0	3
Musculoskeletal chest pain			
subjects affected / exposed	2 / 29 (6.90%)	1 / 2 (50.00%)	1 / 29 (3.45%)
occurrences (all)	2	1	1
Musculoskeletal pain			
subjects affected / exposed	4 / 29 (13.79%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	4	0	0
Myalgia			
subjects affected / exposed	5 / 29 (17.24%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	5	0	1
Neck pain			
subjects affected / exposed	3 / 29 (10.34%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	3	0	0
Pain in extremity			
subjects affected / exposed	7 / 29 (24.14%)	1 / 2 (50.00%)	4 / 29 (13.79%)
occurrences (all)	9	2	4
Spinal pain			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Spondylolisthesis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Tendonitis			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	2	0	1
Amyotrophy			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Fistula			

subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Flank pain			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Intervertebral disc compression			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Joint swelling			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Myositis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Osteoarthritis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Periarthritis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Polymyalgia rheumatica			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Tendon disorder			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Joint instability			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Joint stiffness			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Bacteraemia			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0

Bacterial vaginosis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Cellulitis			
subjects affected / exposed	4 / 29 (13.79%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	4	0	1
Clostridium bacteraemia			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Folliculitis			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	2	0	0
Furuncle			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Gastroenteritis norovirus			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Herpes simplex			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Klebsiella bacteraemia			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Klebsiella infection			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Molluscum contagiosum			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Oral candidiasis			
subjects affected / exposed	3 / 29 (10.34%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	3	0	0
Osteomyelitis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1

Otitis externa			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Otitis media			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Perineal abscess			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	2	0	0
Phlebitis infective			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Pneumonia			
subjects affected / exposed	2 / 29 (6.90%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	2	0	0
Rash pustular			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Sinusitis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	2 / 29 (6.90%)
occurrences (all)	0	0	2
Skin infection			
subjects affected / exposed	3 / 29 (10.34%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	3	0	0
Staphylococcal infection			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Upper respiratory tract infection			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	3 / 29 (10.34%)
occurrences (all)	1	0	3
Upper respiratory tract infection bacterial			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Urinary tract infection			

subjects affected / exposed	2 / 29 (6.90%)	1 / 2 (50.00%)	4 / 29 (13.79%)
occurrences (all)	2	1	4
Abscess oral			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Acute sinusitis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Bronchitis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Catheter site infection			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Corona virus infection			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Cystitis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Cystitis bacterial			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Device related infection			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Diverticulitis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Enterococcal bacteraemia			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Erysipelas			

subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Escherichia urinary tract infection			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis viral			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Herpes zoster			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Hordeolum			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Laryngitis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Lung infection			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Nasopharyngitis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Oesophageal candidiasis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Oral fungal infection			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Parainfluenzae virus infection			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Paronychia			

subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Pharyngitis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Pyelonephritis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Respiratory tract infection viral			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Rhinitis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Soft tissue infection			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Subcutaneous abscess			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Tinea infection			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Tooth abscess			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Tooth infection			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Urinary tract infection enterococcal			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Viral infection			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Fungal skin infection			

subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Influenza			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Lip infection			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Oral herpes			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	7 / 29 (24.14%)	1 / 2 (50.00%)	8 / 29 (27.59%)
occurrences (all)	8	1	8
Dehydration			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Diabetes mellitus			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Fluid overload			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	1	0	1
Hyperglycaemia			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	3 / 29 (10.34%)
occurrences (all)	0	0	3
Hyperkalaemia			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	2 / 29 (6.90%)
occurrences (all)	0	0	5
Hypernatraemia			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Hyperphosphataemia			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	1	0	1

Hypertriglyceridaemia			
subjects affected / exposed	11 / 29 (37.93%)	1 / 2 (50.00%)	14 / 29 (48.28%)
occurrences (all)	20	4	30
Hyperuricaemia			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Hypoalbuminaemia			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	2 / 29 (6.90%)
occurrences (all)	1	0	2
Hypocalcaemia			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Hypokalaemia			
subjects affected / exposed	3 / 29 (10.34%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	3	0	2
Hypomagnesaemia			
subjects affected / exposed	2 / 29 (6.90%)	0 / 2 (0.00%)	2 / 29 (6.90%)
occurrences (all)	2	0	2
Hyponatraemia			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	3 / 29 (10.34%)
occurrences (all)	1	0	4
Hypophosphataemia			
subjects affected / exposed	1 / 29 (3.45%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	1	0	1
Vitamin D deficiency			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Failure to thrive			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Gout			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Hypercholesterolaemia			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0

Hypoglycaemia			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Hypovolaemia			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Lactic acidosis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Malnutrition			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Metabolic alkalosis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Tumour lysis syndrome			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Glucose tolerance impaired			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Hypercalcaemia			
subjects affected / exposed	0 / 29 (0.00%)	0 / 2 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Newly Diagnosed Non-APL AML: Tamibarotene and Azacitidine	R/R non-APL AML: Tamibarotene and Azacitidine	R/R non-APL AML or R/R HR-MDS: Tamibarotene and Daratumumab
Total subjects affected by non-serious adverse events			
subjects affected / exposed	50 / 51 (98.04%)	27 / 28 (96.43%)	15 / 16 (93.75%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Fibrous histiocytoma			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Superficial spreading melanoma stage unspecified			

subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Anal cancer			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Endometrial cancer			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Squamous cell carcinoma of skin			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Vascular disorders			
Pallor			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Vascular insufficiency			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Venous thrombosis			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Hypertension			
subjects affected / exposed	3 / 51 (5.88%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences (all)	6	0	2
Hypotension			
subjects affected / exposed	6 / 51 (11.76%)	1 / 28 (3.57%)	1 / 16 (6.25%)
occurrences (all)	7	4	1
Deep vein thrombosis			
subjects affected / exposed	2 / 51 (3.92%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	2	0	0
Haematoma			
subjects affected / exposed	0 / 51 (0.00%)	4 / 28 (14.29%)	0 / 16 (0.00%)
occurrences (all)	0	4	0
Thrombophlebitis superficial			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0

Thrombosis			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Hot flush			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Erythema			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Surgical and medical procedures			
Shoulder arthroplasty			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
General disorders and administration site conditions			
Adverse drug reaction			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Asthenia			
subjects affected / exposed	11 / 51 (21.57%)	5 / 28 (17.86%)	0 / 16 (0.00%)
occurrences (all)	15	11	0
Catheter site erythema			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Catheter site pain			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences (all)	1	0	1
Chills			
subjects affected / exposed	2 / 51 (3.92%)	4 / 28 (14.29%)	0 / 16 (0.00%)
occurrences (all)	2	5	0
Crepitations			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Device related thrombosis			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Exercise tolerance decreased			

subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Facial pain			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Fatigue			
subjects affected / exposed	19 / 51 (37.25%)	9 / 28 (32.14%)	4 / 16 (25.00%)
occurrences (all)	34	13	5
Gait disturbance			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences (all)	1	0	1
Injection site bruising			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Injection site haemorrhage			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Malaise			
subjects affected / exposed	2 / 51 (3.92%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	2	0	0
Medical device pain			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Medical device site erythema			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Oedema peripheral			
subjects affected / exposed	19 / 51 (37.25%)	4 / 28 (14.29%)	4 / 16 (25.00%)
occurrences (all)	24	7	4
Pain			
subjects affected / exposed	2 / 51 (3.92%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences (all)	3	0	1
Pyrexia			
subjects affected / exposed	17 / 51 (33.33%)	6 / 28 (21.43%)	1 / 16 (6.25%)
occurrences (all)	32	8	2
Catheter site rash			

subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Chest pain			
subjects affected / exposed	1 / 51 (1.96%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	1	1	0
General physical health deterioration			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Impaired healing			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Inflammatory pain			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Injection site erythema			
subjects affected / exposed	3 / 51 (5.88%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	3	0	0
Injection site irritation			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Injection site nodule			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Injection site pain			
subjects affected / exposed	1 / 51 (1.96%)	3 / 28 (10.71%)	0 / 16 (0.00%)
occurrences (all)	1	3	0
Injection site reaction			
subjects affected / exposed	2 / 51 (3.92%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	2	1	0
Localised oedema			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Mucosal inflammation			
subjects affected / exposed	2 / 51 (3.92%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	2	1	0
Non-cardiac chest pain			

subjects affected / exposed	2 / 51 (3.92%)	2 / 28 (7.14%)	0 / 16 (0.00%)
occurrences (all)	3	2	0
Peripheral swelling			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Systemic inflammatory response syndrome			
subjects affected / exposed	1 / 51 (1.96%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	1	2	0
Catheter site swelling			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Early satiety			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Immune system disorders			
Acute graft versus host disease			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Reproductive system and breast disorders			
Pelvic pain			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Vulvovaginal pain			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Ovarian vein thrombosis			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Perineal pain			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Postmenopausal haemorrhage			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Vaginal haemorrhage			

subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Respiratory, thoracic and mediastinal disorders			
Bronchiectasis			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Cough			
subjects affected / exposed	9 / 51 (17.65%)	3 / 28 (10.71%)	3 / 16 (18.75%)
occurrences (all)	10	5	5
Dyspnoea			
subjects affected / exposed	13 / 51 (25.49%)	6 / 28 (21.43%)	3 / 16 (18.75%)
occurrences (all)	19	8	4
Dyspnoea exertional			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	2 / 16 (12.50%)
occurrences (all)	1	0	2
Epistaxis			
subjects affected / exposed	5 / 51 (9.80%)	7 / 28 (25.00%)	2 / 16 (12.50%)
occurrences (all)	7	9	2
Hypopnoea			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Hypoxia			
subjects affected / exposed	1 / 51 (1.96%)	2 / 28 (7.14%)	0 / 16 (0.00%)
occurrences (all)	2	3	0
Lung disorder			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Nasal congestion			
subjects affected / exposed	2 / 51 (3.92%)	3 / 28 (10.71%)	1 / 16 (6.25%)
occurrences (all)	2	3	2
Nasal dryness			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Oropharyngeal pain			

subjects affected / exposed	4 / 51 (7.84%)	1 / 28 (3.57%)	1 / 16 (6.25%)
occurrences (all)	4	1	1
Pleural effusion			
subjects affected / exposed	2 / 51 (3.92%)	3 / 28 (10.71%)	0 / 16 (0.00%)
occurrences (all)	2	3	0
Productive cough			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Rales			
subjects affected / exposed	0 / 51 (0.00%)	3 / 28 (10.71%)	0 / 16 (0.00%)
occurrences (all)	0	3	0
Rhonchi			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Sneezing			
subjects affected / exposed	0 / 51 (0.00%)	2 / 28 (7.14%)	1 / 16 (6.25%)
occurrences (all)	0	2	1
Upper-airway cough syndrome			
subjects affected / exposed	1 / 51 (1.96%)	2 / 28 (7.14%)	0 / 16 (0.00%)
occurrences (all)	1	2	0
Wheezing			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Tachypnoea			
subjects affected / exposed	0 / 51 (0.00%)	2 / 28 (7.14%)	1 / 16 (6.25%)
occurrences (all)	0	2	1
Tonsillar hypertrophy			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Acute promyelocytic leukaemia differentiation syndrome			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Acute pulmonary oedema			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0

Chronic obstructive pulmonary disease			
subjects affected / exposed	2 / 51 (3.92%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	2	0	0
Dysphonia			
subjects affected / exposed	1 / 51 (1.96%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	1	1	0
Laryngeal haemorrhage			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Lung consolidation			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Pleuritic pain			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Pulmonary embolism			
subjects affected / exposed	2 / 51 (3.92%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	2	0	0
Pulmonary mass			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Pulmonary oedema			
subjects affected / exposed	1 / 51 (1.96%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	2	1	0
Respiratory acidosis			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Respiratory distress			
subjects affected / exposed	2 / 51 (3.92%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	2	0	0
Respiratory failure			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Rhinorrhoea			

subjects affected / exposed	3 / 51 (5.88%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	3	0	0
Haemoptysis			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Pneumothorax			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Nasal mucosal ulcer			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Laryngospasm			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Psychiatric disorders			
Anxiety			
subjects affected / exposed	6 / 51 (11.76%)	2 / 28 (7.14%)	0 / 16 (0.00%)
occurrences (all)	6	2	0
Confusional state			
subjects affected / exposed	4 / 51 (7.84%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	4	0	0
Delirium			
subjects affected / exposed	1 / 51 (1.96%)	3 / 28 (10.71%)	0 / 16 (0.00%)
occurrences (all)	1	3	0
Depression			
subjects affected / exposed	4 / 51 (7.84%)	0 / 28 (0.00%)	2 / 16 (12.50%)
occurrences (all)	4	0	2
Hallucination			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Insomnia			
subjects affected / exposed	6 / 51 (11.76%)	2 / 28 (7.14%)	2 / 16 (12.50%)
occurrences (all)	8	3	2
Hallucination, Visual acuity reduced			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0

Mental status changes			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Panic attack			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Psychomotor retardation			
subjects affected / exposed	0 / 51 (0.00%)	2 / 28 (7.14%)	0 / 16 (0.00%)
occurrences (all)	0	3	0
Genito-pelvic pain/penetration disorder			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Hallucination, Olfactory			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Investigations			
Activated partial thromboplastin time prolonged			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Alanine aminotransferase increased			
subjects affected / exposed	4 / 51 (7.84%)	2 / 28 (7.14%)	1 / 16 (6.25%)
occurrences (all)	8	2	1
Amylase increased			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	3
Aspartate aminotransferase increased			
subjects affected / exposed	2 / 51 (3.92%)	2 / 28 (7.14%)	1 / 16 (6.25%)
occurrences (all)	3	2	1
Blood cholesterol increased			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences (all)	5	0	1
Blood creatinine increased			
subjects affected / exposed	4 / 51 (7.84%)	2 / 28 (7.14%)	0 / 16 (0.00%)
occurrences (all)	4	3	0
Blood phosphorus decreased			

subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Blood thyroid stimulating hormone increased			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Blood triglycerides increased			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Breath sounds abnormal			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Cardiac murmur			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Ejection fraction decreased			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
High density lipoprotein decreased			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
International normalised ratio increased			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	2 / 16 (12.50%)
occurrences (all)	0	0	2
Lipase decreased			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Lipase increased			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Neutrophil count decreased			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences (all)	7	0	2
Platelet count decreased			

subjects affected / exposed	4 / 51 (7.84%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences (all)	9	0	5
Respiratory rate increased			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Skin turgor decreased			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Vitamin K decreased			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Weight decreased			
subjects affected / exposed	18 / 51 (35.29%)	5 / 28 (17.86%)	1 / 16 (6.25%)
occurrences (all)	28	9	2
White blood cell count decreased			
subjects affected / exposed	2 / 51 (3.92%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences (all)	6	0	1
Blood bilirubin increased			
subjects affected / exposed	2 / 51 (3.92%)	2 / 28 (7.14%)	0 / 16 (0.00%)
occurrences (all)	4	2	0
Blood uric acid increased			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Coronavirus test positive			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Electrocardiogram QT prolonged			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences (all)	1	0	1
Respiratory syncytial virus test positive			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Troponin I increased			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0

Blood alkaline phosphatase increased			
subjects affected / exposed	2 / 51 (3.92%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences (all)	3	0	1
Chest X-ray abnormal			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Heart rate irregular			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	2 / 16 (12.50%)
occurrences (all)	0	0	2
Lymphocyte count decreased			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	9 / 51 (17.65%)	3 / 28 (10.71%)	1 / 16 (6.25%)
occurrences (all)	9	3	1
Excoriation			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Eye injury			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Fall			
subjects affected / exposed	7 / 51 (13.73%)	5 / 28 (17.86%)	1 / 16 (6.25%)
occurrences (all)	8	10	3
Joint dislocation			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Laceration			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Post procedural haematoma			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Rib fracture			

subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Scratch			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Animal bite			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Eschar			
subjects affected / exposed	2 / 51 (3.92%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	2	1	0
Face injury			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Lumbar vertebral fracture			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	2	0	0
Procedural pain			
subjects affected / exposed	2 / 51 (3.92%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	2	1	0
Procedural site reaction			
subjects affected / exposed	2 / 51 (3.92%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	2	0	0
Road traffic accident			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Transfusion reaction			
subjects affected / exposed	2 / 51 (3.92%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences (all)	2	0	1
Transfusion-related circulatory overload			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	0	2	0
Wrist fracture			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0

Infusion related reaction			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	5 / 16 (31.25%)
occurrences (all)	0	0	5
Periorbital haemorrhage			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Skin abrasion			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Thermal burn			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Congenital, familial and genetic disorders			
Macroglossia			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Cardiac disorders			
Angina pectoris			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Atrial fibrillation			
subjects affected / exposed	2 / 51 (3.92%)	3 / 28 (10.71%)	0 / 16 (0.00%)
occurrences (all)	2	3	0
Atrial flutter			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Atrial tachycardia			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Bradycardia			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	2	0	0
Nodal rhythm			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Palpitations			

subjects affected / exposed	3 / 51 (5.88%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	3	1	0
Sinus bradycardia			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Sinus tachycardia			
subjects affected / exposed	0 / 51 (0.00%)	2 / 28 (7.14%)	2 / 16 (12.50%)
occurrences (all)	0	2	2
Tachycardia			
subjects affected / exposed	2 / 51 (3.92%)	1 / 28 (3.57%)	1 / 16 (6.25%)
occurrences (all)	3	1	1
Angina unstable			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Cardiac arrest			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Cardiac failure			
subjects affected / exposed	1 / 51 (1.96%)	1 / 28 (3.57%)	1 / 16 (6.25%)
occurrences (all)	1	1	1
Cardiomyopathy			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Coronary artery insufficiency			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Left ventricular dysfunction			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Pericardial effusion			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Ventricular hypokinesia			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Pericarditis			

subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Nervous system disorders			
Cerebrovascular accident			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Cognitive disorder			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Cranial nerve disorder			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Disturbance in attention			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Dizziness			
subjects affected / exposed	11 / 51 (21.57%)	4 / 28 (14.29%)	0 / 16 (0.00%)
occurrences (all)	15	8	0
Dizziness postural			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Dysgeusia			
subjects affected / exposed	4 / 51 (7.84%)	3 / 28 (10.71%)	0 / 16 (0.00%)
occurrences (all)	5	3	0
Encephalopathy			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Facial paresis			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Haemorrhage intracranial			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Headache			
subjects affected / exposed	6 / 51 (11.76%)	3 / 28 (10.71%)	1 / 16 (6.25%)
occurrences (all)	8	4	1

Memory impairment			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Neuropathy peripheral			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Paraesthesia			
subjects affected / exposed	1 / 51 (1.96%)	1 / 28 (3.57%)	1 / 16 (6.25%)
occurrences (all)	1	1	1
Peripheral sensory neuropathy			
subjects affected / exposed	1 / 51 (1.96%)	1 / 28 (3.57%)	1 / 16 (6.25%)
occurrences (all)	2	1	1
Presyncope			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Seizure			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Sinus headache			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Speech disorder			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Syncope			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Tongue paralysis			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Tremor			
subjects affected / exposed	2 / 51 (3.92%)	1 / 28 (3.57%)	1 / 16 (6.25%)
occurrences (all)	3	2	1
Ageusia			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0

Akathisia			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Ataxia			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Balance disorder			
subjects affected / exposed	1 / 51 (1.96%)	1 / 28 (3.57%)	1 / 16 (6.25%)
occurrences (all)	2	1	1
Carotid artery thrombosis			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Coordination abnormal			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Nerve compression			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Cerebellar syndrome			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Epilepsy			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Hyperaesthesia			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Hypogeusia			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Lethargy			
subjects affected / exposed	1 / 51 (1.96%)	2 / 28 (7.14%)	0 / 16 (0.00%)
occurrences (all)	3	3	0
Parkinson's disease			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0

Parkinsonism			
subjects affected / exposed	1 / 51 (1.96%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	1	1	0
Partial seizures			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Sciatica			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Somnolence			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	13 / 51 (25.49%)	5 / 28 (17.86%)	4 / 16 (25.00%)
occurrences (all)	40	12	11
Febrile neutropenia			
subjects affected / exposed	2 / 51 (3.92%)	3 / 28 (10.71%)	0 / 16 (0.00%)
occurrences (all)	2	3	0
Increased tendency to bruise			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Lymphadenopathy			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Neutropenia			
subjects affected / exposed	9 / 51 (17.65%)	2 / 28 (7.14%)	1 / 16 (6.25%)
occurrences (all)	25	18	1
Splenic lesion			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Thrombocytopenia			
subjects affected / exposed	12 / 51 (23.53%)	2 / 28 (7.14%)	6 / 16 (37.50%)
occurrences (all)	32	4	30
Disseminated intravascular coagulation			

subjects affected / exposed	2 / 51 (3.92%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	2	0	0
Leukopenia			
subjects affected / exposed	9 / 51 (17.65%)	2 / 28 (7.14%)	4 / 16 (25.00%)
occurrences (all)	18	3	13
Lymph node pain			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Lymphopenia			
subjects affected / exposed	1 / 51 (1.96%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	2	1	0
Splenomegaly			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Thrombocytopenic purpura			
subjects affected / exposed	1 / 51 (1.96%)	1 / 28 (3.57%)	1 / 16 (6.25%)
occurrences (all)	1	1	1
Thymus disorder			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Ear and labyrinth disorders			
Ear discomfort			
subjects affected / exposed	0 / 51 (0.00%)	2 / 28 (7.14%)	0 / 16 (0.00%)
occurrences (all)	0	2	0
Ear pain			
subjects affected / exposed	0 / 51 (0.00%)	3 / 28 (10.71%)	1 / 16 (6.25%)
occurrences (all)	0	3	1
Excessive cerumen production			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
External ear pain			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Hypoacusis			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0

Mastoid effusion			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Cerumen impaction			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Deafness unilateral			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	2	0	0
Vertigo			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Eye disorders			
Cataract			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Conjunctival haemorrhage			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Dry eye			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Eye disorder			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Eye irritation			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Eye pain			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Retinal haemorrhage			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Retinal vascular disorder			

subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Vision blurred			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Exophthalmos			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Ocular hyperaemia			
subjects affected / exposed	1 / 51 (1.96%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	1	1	0
Photophobia			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Blindness			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Abdominal distension			
subjects affected / exposed	0 / 51 (0.00%)	2 / 28 (7.14%)	2 / 16 (12.50%)
occurrences (all)	0	2	2
Abdominal pain			
subjects affected / exposed	6 / 51 (11.76%)	3 / 28 (10.71%)	3 / 16 (18.75%)
occurrences (all)	7	4	3
Abdominal rigidity			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Ascites			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	24 / 51 (47.06%)	10 / 28 (35.71%)	2 / 16 (12.50%)
occurrences (all)	30	15	2

Diarrhoea			
subjects affected / exposed	17 / 51 (33.33%)	11 / 28 (39.29%)	3 / 16 (18.75%)
occurrences (all)	25	15	3
Dry mouth			
subjects affected / exposed	5 / 51 (9.80%)	3 / 28 (10.71%)	0 / 16 (0.00%)
occurrences (all)	5	3	0
Dyspepsia			
subjects affected / exposed	3 / 51 (5.88%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	4	1	0
Dysphagia			
subjects affected / exposed	3 / 51 (5.88%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	4	0	0
Flatulence			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Gastrointestinal haemorrhage			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	2	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	3 / 51 (5.88%)	2 / 28 (7.14%)	0 / 16 (0.00%)
occurrences (all)	3	2	0
Gingival bleeding			
subjects affected / exposed	2 / 51 (3.92%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	2	0	0
Haematochezia			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Lip dry			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Mouth ulceration			
subjects affected / exposed	2 / 51 (3.92%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	2	1	0
Nausea			
subjects affected / exposed	24 / 51 (47.06%)	14 / 28 (50.00%)	5 / 16 (31.25%)
occurrences (all)	25	18	5

Oral pain			
subjects affected / exposed	1 / 51 (1.96%)	1 / 28 (3.57%)	1 / 16 (6.25%)
occurrences (all)	1	1	1
Rectal ulcer			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Stomatitis			
subjects affected / exposed	1 / 51 (1.96%)	4 / 28 (14.29%)	1 / 16 (6.25%)
occurrences (all)	1	6	1
Toothache			
subjects affected / exposed	1 / 51 (1.96%)	3 / 28 (10.71%)	0 / 16 (0.00%)
occurrences (all)	1	3	0
Vomiting			
subjects affected / exposed	11 / 51 (21.57%)	9 / 28 (32.14%)	6 / 16 (37.50%)
occurrences (all)	13	17	7
Abdominal pain upper			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences (all)	1	0	1
Anal fissure			
subjects affected / exposed	2 / 51 (3.92%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	2	0	0
Angina bullosa haemorrhagica			
subjects affected / exposed	0 / 51 (0.00%)	2 / 28 (7.14%)	0 / 16 (0.00%)
occurrences (all)	0	3	0
Aphthous ulcer			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	2	0	0
Faecaloma			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Gastritis			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Haemorrhoids			
subjects affected / exposed	5 / 51 (9.80%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	6	0	0

Inguinal hernia			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Lip swelling			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Melaena			
subjects affected / exposed	1 / 51 (1.96%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	1	1	0
Mouth haemorrhage			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	1 / 16 (6.25%)
occurrences (all)	0	1	1
Noninfective gingivitis			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Oral mucosal blistering			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	1 / 16 (6.25%)
occurrences (all)	0	1	1
Pancreatitis			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Periodontal disease			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Proctalgia			
subjects affected / exposed	2 / 51 (3.92%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	2	0	0
Rectal haemorrhage			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	2	0	0
Tongue haematoma			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Lip haemorrhage			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0

Gingival pain			
subjects affected / exposed	0 / 51 (0.00%)	2 / 28 (7.14%)	0 / 16 (0.00%)
occurrences (all)	0	2	0
Hepatobiliary disorders			
Cholelithiasis			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Hyperbilirubinaemia			
subjects affected / exposed	2 / 51 (3.92%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences (all)	3	0	1
Hepatic cirrhosis			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	8 / 51 (15.69%)	2 / 28 (7.14%)	1 / 16 (6.25%)
occurrences (all)	12	4	1
Blister			
subjects affected / exposed	1 / 51 (1.96%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	1	1	0
Cold sweat			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	10 / 51 (19.61%)	5 / 28 (17.86%)	3 / 16 (18.75%)
occurrences (all)	14	5	3
Hyperhidrosis			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Night sweat			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences (all)	2	0	1
Onychomadesis			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Papule			

subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Petechiae			
subjects affected / exposed	3 / 51 (5.88%)	5 / 28 (17.86%)	1 / 16 (6.25%)
occurrences (all)	3	5	1
Pruritus			
subjects affected / exposed	12 / 51 (23.53%)	5 / 28 (17.86%)	0 / 16 (0.00%)
occurrences (all)	16	5	0
Purpura			
subjects affected / exposed	3 / 51 (5.88%)	3 / 28 (10.71%)	1 / 16 (6.25%)
occurrences (all)	3	3	1
Rash			
subjects affected / exposed	5 / 51 (9.80%)	1 / 28 (3.57%)	3 / 16 (18.75%)
occurrences (all)	6	1	3
Rash generalised			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Rash maculo-papular			
subjects affected / exposed	5 / 51 (9.80%)	2 / 28 (7.14%)	0 / 16 (0.00%)
occurrences (all)	10	4	0
Rash pruritic			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	2	0	0
Skin discolouration			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Skin hyperpigmentation			
subjects affected / exposed	2 / 51 (3.92%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	2	0	0
Skin induration			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Skin lesion			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Skin mass			

subjects affected / exposed	1 / 51 (1.96%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	1	1	0
Skin necrosis			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Skin ulcer			
subjects affected / exposed	2 / 51 (3.92%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	2	0	0
Eczema			
subjects affected / exposed	2 / 51 (3.92%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	3	0	0
Hyperkeratosis			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Nodular rash			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Prurigo			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Pruritus generalised			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Pyoderma gangrenosum			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Rash erythematous			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Scab			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Skin erosion			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Skin exfoliation			

subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Stasis dermatitis			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Sticky skin			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Urticaria			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Rash papular			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Chronic papillomatous dermatitis			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Dermatitis psoriasiform			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Dermatitis bullous			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Drug eruption			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	3 / 51 (5.88%)	3 / 28 (10.71%)	0 / 16 (0.00%)
occurrences (all)	4	5	0
Chromaturia			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Dysuria			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	0	1	0

Micturition urgency			
subjects affected / exposed	1 / 51 (1.96%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	1	1	0
Nocturia			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Pollakiuria			
subjects affected / exposed	1 / 51 (1.96%)	3 / 28 (10.71%)	1 / 16 (6.25%)
occurrences (all)	1	3	1
Proteinuria			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Urinary tract pain			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Urine odour abnormal			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Chronic kidney disease			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Haematuria			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Incontinence			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Urethral stenosis			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Urinary hesitation			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Urinary incontinence			
subjects affected / exposed	1 / 51 (1.96%)	2 / 28 (7.14%)	0 / 16 (0.00%)
occurrences (all)	1	3	0

Urinary retention			
subjects affected / exposed	4 / 51 (7.84%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	4	0	0
Urine flow decreased			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Endocrine disorders			
Cushingoid			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Hypothyroidism			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	13 / 51 (25.49%)	7 / 28 (25.00%)	3 / 16 (18.75%)
occurrences (all)	15	11	4
Arthritis			
subjects affected / exposed	2 / 51 (3.92%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	2	0	0
Back pain			
subjects affected / exposed	9 / 51 (17.65%)	1 / 28 (3.57%)	2 / 16 (12.50%)
occurrences (all)	11	1	2
Bone pain			
subjects affected / exposed	2 / 51 (3.92%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences (all)	2	0	1
Bursitis			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Groin pain			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Intervertebral disc protrusion			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Joint range of motion decreased			

subjects affected / exposed	2 / 51 (3.92%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	3	1	0
Muscle spasms			
subjects affected / exposed	1 / 51 (1.96%)	1 / 28 (3.57%)	1 / 16 (6.25%)
occurrences (all)	1	1	1
Muscular weakness			
subjects affected / exposed	4 / 51 (7.84%)	2 / 28 (7.14%)	1 / 16 (6.25%)
occurrences (all)	5	4	2
Musculoskeletal chest pain			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences (all)	1	0	1
Musculoskeletal pain			
subjects affected / exposed	9 / 51 (17.65%)	3 / 28 (10.71%)	0 / 16 (0.00%)
occurrences (all)	11	3	0
Myalgia			
subjects affected / exposed	5 / 51 (9.80%)	4 / 28 (14.29%)	3 / 16 (18.75%)
occurrences (all)	6	7	3
Neck pain			
subjects affected / exposed	2 / 51 (3.92%)	2 / 28 (7.14%)	0 / 16 (0.00%)
occurrences (all)	2	3	0
Pain in extremity			
subjects affected / exposed	7 / 51 (13.73%)	3 / 28 (10.71%)	2 / 16 (12.50%)
occurrences (all)	11	3	2
Spinal pain			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Spondylolisthesis			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Tendonitis			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Amyotrophy			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Fistula			

subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Flank pain			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Intervertebral disc compression			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Joint swelling			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Myositis			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	2	0	0
Osteoarthritis			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	2	0	0
Periarthritis			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	2	0	0
Polymyalgia rheumatica			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Tendon disorder			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	2	0	0
Joint instability			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Joint stiffness			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Infections and infestations			
Bacteraemia			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0

Bacterial vaginosis			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Cellulitis			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Clostridium bacteraemia			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Folliculitis			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Furuncle			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Gastroenteritis norovirus			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Herpes simplex			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Klebsiella bacteraemia			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Klebsiella infection			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Molluscum contagiosum			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Oral candidiasis			
subjects affected / exposed	4 / 51 (7.84%)	3 / 28 (10.71%)	0 / 16 (0.00%)
occurrences (all)	4	4	0
Osteomyelitis			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0

Otitis externa			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Otitis media			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Perineal abscess			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Phlebitis infective			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Pneumonia			
subjects affected / exposed	1 / 51 (1.96%)	3 / 28 (10.71%)	0 / 16 (0.00%)
occurrences (all)	1	3	0
Rash pustular			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Sinusitis			
subjects affected / exposed	2 / 51 (3.92%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	2	0	0
Skin infection			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Staphylococcal infection			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	2 / 51 (3.92%)	0 / 28 (0.00%)	2 / 16 (12.50%)
occurrences (all)	2	0	2
Upper respiratory tract infection bacterial			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Urinary tract infection			

subjects affected / exposed	3 / 51 (5.88%)	2 / 28 (7.14%)	1 / 16 (6.25%)
occurrences (all)	3	4	1
Abscess oral			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Acute sinusitis			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Bronchitis			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Catheter site infection			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Conjunctivitis			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Corona virus infection			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Cystitis			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Cystitis bacterial			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Device related infection			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	2	0	0
Diverticulitis			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Enterococcal bacteraemia			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	2	0	0
Erysipelas			

subjects affected / exposed	1 / 51 (1.96%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	1	1	0
Escherichia urinary tract infection			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Gastroenteritis			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Gastroenteritis viral			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Herpes zoster			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Hordeolum			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Laryngitis			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Lung infection			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Nasopharyngitis			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Oesophageal candidiasis			
subjects affected / exposed	1 / 51 (1.96%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	1	1	0
Oral fungal infection			
subjects affected / exposed	2 / 51 (3.92%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	3	1	0
Parainfluenzae virus infection			
subjects affected / exposed	2 / 51 (3.92%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	2	0	0
Paronychia			

subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Pharyngitis			
subjects affected / exposed	3 / 51 (5.88%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	3	0	0
Pyelonephritis			
subjects affected / exposed	2 / 51 (3.92%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	2	0	0
Respiratory tract infection viral			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Rhinitis			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Soft tissue infection			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Subcutaneous abscess			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	2	0	0
Tinea infection			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Tooth abscess			
subjects affected / exposed	1 / 51 (1.96%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	1	1	0
Tooth infection			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Urinary tract infection enterococcal			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Viral infection			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Fungal skin infection			

subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Influenza			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Lip infection			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Oral herpes			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	2 / 16 (12.50%)
occurrences (all)	0	0	3
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	24 / 51 (47.06%)	9 / 28 (32.14%)	3 / 16 (18.75%)
occurrences (all)	35	10	4
Dehydration			
subjects affected / exposed	4 / 51 (7.84%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	4	0	0
Diabetes mellitus			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Fluid overload			
subjects affected / exposed	1 / 51 (1.96%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	1	1	0
Hyperglycaemia			
subjects affected / exposed	4 / 51 (7.84%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	5	0	0
Hyperkalaemia			
subjects affected / exposed	5 / 51 (9.80%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences (all)	6	0	1
Hypernatraemia			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Hyperphosphataemia			
subjects affected / exposed	2 / 51 (3.92%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	2	0	0

Hypertriglyceridaemia			
subjects affected / exposed	21 / 51 (41.18%)	8 / 28 (28.57%)	5 / 16 (31.25%)
occurrences (all)	68	17	6
Hyperuricaemia			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Hypoalbuminaemia			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Hypocalcaemia			
subjects affected / exposed	2 / 51 (3.92%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	7	2	0
Hypokalaemia			
subjects affected / exposed	13 / 51 (25.49%)	0 / 28 (0.00%)	3 / 16 (18.75%)
occurrences (all)	15	0	3
Hypomagnesaemia			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	2 / 16 (12.50%)
occurrences (all)	0	0	2
Hyponatraemia			
subjects affected / exposed	3 / 51 (5.88%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	4	0	0
Hypophosphataemia			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences (all)	1	0	1
Vitamin D deficiency			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Failure to thrive			
subjects affected / exposed	1 / 51 (1.96%)	2 / 28 (7.14%)	0 / 16 (0.00%)
occurrences (all)	1	2	0
Gout			
subjects affected / exposed	2 / 51 (3.92%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	2	0	0
Hypercholesterolaemia			
subjects affected / exposed	3 / 51 (5.88%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	4	0	0

Hypoglycaemia			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Hypovolaemia			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Lactic acidosis			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Malnutrition			
subjects affected / exposed	2 / 51 (3.92%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	2	0	0
Metabolic alkalosis			
subjects affected / exposed	0 / 51 (0.00%)	1 / 28 (3.57%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Tumour lysis syndrome			
subjects affected / exposed	2 / 51 (3.92%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	3	0	0
Glucose tolerance impaired			
subjects affected / exposed	0 / 51 (0.00%)	0 / 28 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Hypercalcaemia			
subjects affected / exposed	1 / 51 (1.96%)	0 / 28 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
23 August 2016	The study design was changed to include 2 additional participant populations: - Newly diagnosed, treatment naïve older participants with non-APL AML who were unlikely to respond to or tolerate standard therapies - Participants with transfusion-dependent LR-MDS without the del 5q abnormality who were refractory to EPO treatment or unlikely to respond to EPO treatment - The study design was changed from a 1-arm study with 2 cohorts stratified by biomarker status into a 4-arm study. - The number of participants to be enrolled was increased to approximately 80 response-evaluable participants enrolling into 4 arms of approximately 20 participants each - Study objectives and endpoints, eligibility criteria, study schema, Schedule of Events, and statistics were updated to align with the revised study design. - The study was updated to exclude use of strong inducers of Cytochrome P450 3A4 (CYP3A4) within 2 weeks prior to first study treatment and throughout the study
20 March 2017	- The study design was changed to include an additional arm (Arm 2B) for newly diagnosed, treatment-naïve participants with non-APL AML ≥60 years of age. Participants enrolled in Arm 2B were to receive tamibarotene in combination with azacitidine. - The total number of participants to be enrolled in the study was increased to approximately 100 response-evaluable participants enrolling into 4 arms of approximately 25 participants each. - Participants enrolled in Arms 1, 2A, 2B, and 3 had to be positive for the RARA super-enhancer associated biomarker or IRF8 biomarker. - Newly diagnosed participants with AML enrolled in Arm 2A who achieved a CR, CRi or PR while on tamibarotene monotherapy and then relapsed, or who failed to achieve a CR, CRi or PR after completing at least 4 cycles, were eligible to receive tamibarotene in combination with azacitidine. - Study objectives and endpoints, study schema, statistics, and Schedule of Events were updated to align with the revised study design. - Participants were allowed to enroll in study sites located in both the US and Europe.
07 July 2017	- The eligibility criteria for newly diagnosed participants with AML (Arms 2A and 2B) were revised for consistency with the unfit participant population as described in the Ferrara, et al paper (Ferrara 2013). - Clarification was added that assignment to Arm 2A (single-agent tamibarotene) or Arm 2B (tamibarotene/azacitidine) is determined by investigator choice of treatment.
25 April 2018	- The sample size in Arm 2B was increased from 25 to 50 participants (approximately 25 biomarker positive and 25 biomarker negative). - Clarification was added that the first primary objective/endpoint will be analyzed in biomarker-positive participants. - A secondary objective/endpoint was added to explore the ORR in Arm 2B. - Inclusion criteria were updated to allow participants in Arm 2B to be enrolled regardless of biomarker result. - The statistical section was updated to include calculation to support new secondary endpoint.

29 March 2019	- The protocol was updated to characterize the clinical activity of the tamibarotene and azacitidine combination in biomarker-positive participants with R/R AML. - Update was made to reflect the additional requirements for daratumumab due to a newly identified risk of hepatitis B reactivation as communicated via administrative letter dated 26 December 2018. - Bone marrow sample collection was updated for participants with AML and HR-MDS to enable the assessment of the extent of a CR. - Central laboratory sampling was updated to allow for adequate sampling and accommodating/reducing a participant's time at each visit. - The Schedule of Events for Arm 4 was updated to add an Hepatitis B virus (HBV) serology test for specific participants.
31 August 2022	- The primary reason for this amendment was to provide a means for the last participant on study treatment (Arm 5) to continue to have access to tamibarotene as long as the participant continues to experience clinical benefit and to discontinue survival follow-up collection for all participants still active on study in post-treatment follow-up (all in Arm 2B). - Protocol was revised to describe the study procedure changes resulting from Amendment 7 for Arm 5 and Arm 2B participants who were still participating in the study at the time of the amendment. - Protocol was revised to update the site requirements and instructions for providing tamibarotene accountability records to the sponsor. - The protocol was revised to update the concomitant medication instructions for CYP3A4 inhibitors and inducers, in alignment with recent updates made to the investigator brochure (IB). - The protocol was revised to differentiate between male and female contraceptive requirements in alignment with recent updates made to the IB.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported